Patents by Inventor Steven Shak

Steven Shak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Expression profile algorithm and test for cancer prognosis
    Patent number: 7526387
    Abstract: The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: April 28, 2009
    Assignees: Genomic Health, Inc., NSABP Foundation, Inc.
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • GENE EXPRESSION MARKERS FOR RESPONSE TO EGFR INHIBITOR DRUGS
    Publication number: 20080318230
    Abstract: The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
    Type: Application
    Filed: December 3, 2007
    Publication date: December 25, 2008
    Inventors: David AGUS, Joffre B. Baker, Ron B. Natale, Steven Shak
  • Gene Expression Markers for Response to EGFR Inhibitor Drugs
    Publication number: 20080176229
    Abstract: The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
    Type: Application
    Filed: May 30, 2007
    Publication date: July 24, 2008
    Inventors: David Agus, Steven Shak, Maureen Cronin, Joffre Baker
  • Dosages for treatment with anti-ErbB2 antibodies
    Patent number: 7371379
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: May 13, 2008
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • ANTI-INFECTIVE THERAPY
    Publication number: 20080026426
    Abstract: DNA isolates coding for human DNase and methods of obtaining such DNA are provided, together with expression systems for recombinant production of human DNase useful in therapeutic or diagnostic compositions.
    Type: Application
    Filed: September 27, 2007
    Publication date: January 31, 2008
    Applicant: Genentech, Inc.
    Inventor: Steven Shak
  • Human DNase
    Patent number: 7297526
    Abstract: DNA isolates coding for human DNase and methods of obtaining such DNA are provided, together with expression systems for recombinant production of human DNase useful in therapeutic or diagnostic compositions.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: November 20, 2007
    Assignee: Genentech, Inc.
    Inventor: Steven Shak
  • Prediction of likelihood of cancer recurrence
    Publication number: 20060286565
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
    Type: Application
    Filed: January 31, 2006
    Publication date: December 21, 2006
    Inventors: Joffre Baker, John Bryant, Soonmyung Paik, Steven Shak
  • Dosages for treatment with anti-EGFR antibodies
    Publication number: 20060210561
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: May 31, 2006
    Publication date: September 21, 2006
    Inventors: Sharon Baughman, Steven Shak
  • Molecular indicators of breast cancer prognosis and prediction of treatment response
    Publication number: 20060166231
    Abstract: The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy.
    Type: Application
    Filed: November 4, 2005
    Publication date: July 27, 2006
    Inventors: Joffre Baker, John Bryant, Soonmyung Paik, Steven Shak
  • Predicting response to chemotherapy using gene expression markers
    Publication number: 20060166230
    Abstract: The present invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial response to treatment response with chemotherapy.
    Type: Application
    Filed: November 4, 2005
    Publication date: July 27, 2006
    Inventors: Joffre Baker, John Bryant, Soonmyung Paik, Steven Shak
  • Prediction of likelihood of cancer recurrence
    Patent number: 7056674
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: June 6, 2006
    Assignees: Genomic Health, Inc., NSABP Foundation, Inc.
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Gene expression markers for predicting response to chemotherapy
    Publication number: 20050260646
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy.FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Application
    Filed: April 7, 2005
    Publication date: November 24, 2005
    Applicant: Genomic Health Inc.
    Inventors: Joffre Baker, Steven Shak, Luca Gianni
  • Gene expression markers for response to EGFR inhibitor drugs
    Publication number: 20050164218
    Abstract: The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
    Type: Application
    Filed: May 28, 2004
    Publication date: July 28, 2005
    Inventors: David Agus, Joffre Baker, Ron Natale, Steven Shak
  • Prediction of likelihood of cancer recurrence
    Publication number: 20050079518
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
    Type: Application
    Filed: June 17, 2004
    Publication date: April 14, 2005
    Inventors: Joffre Baker, John Bryant, Soonmyung Paik, Steven Shak
  • Gene expression markers for predicting response to chemotherapy
    Publication number: 20050064455
    Abstract: The invention provides sets of genes the expression of which predicts whether cancer patients are likely to have a beneficial treatment response to chemotherapy.
    Type: Application
    Filed: May 24, 2004
    Publication date: March 24, 2005
    Inventors: Joffre Baker, Kathy Miller, Steven Shak, George Sledge, Sharon Soule
  • Expression profile algorithm and test for cancer prognosis
    Publication number: 20050048542
    Abstract: The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
    Type: Application
    Filed: June 30, 2004
    Publication date: March 3, 2005
    Inventors: Joffre Baker, John Bryant, Soonmyung Paik, Steven Shak
  • Anti-infective therapy
    Publication number: 20050009056
    Abstract: DNA isolates coding for human DNase and methods of obtaining such DNA are provided, together with expression systems for recombinant production of human DNase useful in therapeutic or diagnostic compositions.
    Type: Application
    Filed: May 4, 2004
    Publication date: January 13, 2005
    Inventor: Steven Shak
  • Gene expression markers for response to EGFR inhibitor drugs
    Publication number: 20040157255
    Abstract: The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
    Type: Application
    Filed: February 6, 2004
    Publication date: August 12, 2004
    Inventors: David Agus, Steven Shak, Maureen Cronin, Joffre Baker
  • Treatment with anti-ErbB2 antibodies
    Publication number: 20040037823
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
    Type: Application
    Filed: February 3, 2003
    Publication date: February 26, 2004
    Applicant: Genentech, Inc.
    Inventors: Virginia E. Paton, Steven Shak, Susan D. Hellmann
  • Dosages for treatment with anti-ErbB2 antibodies
    Publication number: 20040037824
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
    Type: Application
    Filed: June 20, 2003
    Publication date: February 26, 2004
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak